CT-guided single high-dose percutaneous acetic acid injection for small hepatocellular carcinoma: A long-term follow-up study

详细信息	查看全文 | 推荐本文 |

• 作者：Heng Ma ; ^{hengma001@yahoo.com.cn} ; Jing Liu ^{583589267@qq.com} ; Fengli Liu ^{1312956609@qq.com}
• 关键词：Hepatocellular carcinoma ; Percutaneous acetic acid injection ; Survival ; Computed tomography ; Prognosis
• 刊名：European Journal of Radiology
• 出版年：2012
• 期刊代码：93_0720048x
• 类别：med
• 出版时间：June, 2012
• 卷：81
• 期：6
• 页码：1184-1186
• 文件大小：355 K

摘要

Objective

To evaluate the long-term outcome of CT-guided single high-dose percutaneous acetic acid injection (PAI) for the treatment of small hepatocellular carcinoma (SHCC).

Materials and methods

Sixty-eight consecutive patients (37 men and 31 women; age 52 卤 16 years) with SHCC have undergone CT-guided single high-dose PAI therapy since December 2000. Complications of high-dose PAI were recorded. Tumour survival and recurrence rates were assessed.

Results

All PAI therapies were successful and no severe complications developed. The average follow-up period was 46 卤 18 months. The overall survival rates at 1, 2, 3, 4 and 5 years were 93%, 82%, 68%, 59%and 51%, respectively. The cumulative local recurrence rates for the main tumour at 1, 2, 3, 4 and 5 years were 18%, 22%, 25%, 28%and 28%, respectively. The cumulative new tumour recurrence rates at 1, 2, 3, 4 and 5 years were 24%, 40%, 43%, 60%and 62%, respectively.

Conclusion

CT-guided single high-dose PAI is safe and effective for the treatment of SHCC after long-term follow-up.